The Neurobiology of Depressive Illness
Primary Purpose
Major Depression
Status
Unknown status
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
antidepressants primarily selective serotonin reuptake inhibitors
Sponsored by
About this trial
This is an interventional treatment trial for Major Depression focused on measuring Major Depression, Cardiac disease
Eligibility Criteria
Inclusion Criteria: Major depression Exclusion Criteria: heart disease diabetes hypertension psychosis significant suicidal risk dementia
Sites / Locations
- Baker Heart Research InstituteRecruiting
Arms of the Study
Arm 1
Arm Type
Active Comparator
Arm Label
intervention
Arm Description
there is no sham or placebo control arm It is a single arm study
Outcomes
Primary Outcome Measures
level of sympathetic nervous system activity and its response to treatment
Secondary Outcome Measures
clinical response to treatment
Full Information
NCT ID
NCT00168493
First Posted
September 10, 2005
Last Updated
May 19, 2008
Sponsor
Baker Heart Research Institute
Collaborators
National Health and Medical Research Council, Australia
1. Study Identification
Unique Protocol Identification Number
NCT00168493
Brief Title
The Neurobiology of Depressive Illness
Official Title
The Neurobiology of Depressive Illness: Causes and Consequences of Altered Brain Monoaminergic Function
Study Type
Interventional
2. Study Status
Record Verification Date
May 2008
Overall Recruitment Status
Unknown status
Study Start Date
June 2000 (undefined)
Primary Completion Date
December 2008 (Anticipated)
Study Completion Date
December 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Baker Heart Research Institute
Collaborators
National Health and Medical Research Council, Australia
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
We aim to determine why patients with depression are at an elevated risk for the development of coronary heart disease, and resolve whether the severity of a patient's depression has a counterpart in demonstrable abnormalities in brain chemistry. Studies will be completed in 28 patients with depression; both males and females. Patients will be studied both untreated and during administration of a selective serotonin re-uptake inhibitor (SSRI) antidepressant. They will be either newly diagnosed with depression, untreated patients suffering a recent relapse, or patients seeking to switch from a non-SSRI antidepressant due to non-response. The turnover of chemical messengers in the brain will be estimated by high internal jugular venous blood sampling and DNA will be isolated and examined from blood cells. Immune function will also be assessed. Whole body and cardiac sympathetic nervous activity will be determined, as well as microneurographic recording of muscle sympathetic nervous activity.
It is hypothesised that patients with depression and no existing demonstrable cardiac disease demonstrate:
Alterations in brain monoaminergic neurotransmitter turnover, resulting in sympathetic nervous activation and dysregulation of the baroreflex control to both the heart (vagal) and muscle vasoconstrictor sympathetic nerves; and Exhibit enhanced platelet reactivity predisposing them to thrombogenesis and myocardial ischaemia.
Therapeutic intervention with an SSRI will modify cardiac sympathetic function, baroreflex sensitivity or platelet reactivity in a fashion likely to reduce cardiac risk.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depression
Keywords
Major Depression, Cardiac disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
intervention
Arm Type
Active Comparator
Arm Description
there is no sham or placebo control arm It is a single arm study
Intervention Type
Drug
Intervention Name(s)
antidepressants primarily selective serotonin reuptake inhibitors
Intervention Description
normal clinical dosages used according to clinical response as determined by a psychiatrist
Primary Outcome Measure Information:
Title
level of sympathetic nervous system activity and its response to treatment
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
clinical response to treatment
Time Frame
12 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Major depression
Exclusion Criteria:
heart disease diabetes hypertension psychosis significant suicidal risk dementia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David A Barton, MBBSFRANZCP
Phone
61393428946
Email
david.barton@bigpond.com
First Name & Middle Initial & Last Name or Official Title & Degree
Murray Esler, PhD Fracp
Phone
61385321338
Email
Murray.Esler@baker.edu.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Murray A Esler, MBBS Phd
Organizational Affiliation
Baker Heart Research Insitute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baker Heart Research Institute
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David A Barton, MBBS
Phone
61393428946
Email
david.barton@bigpond.com
First Name & Middle Initial & Last Name & Degree
David a Barton, m
12. IPD Sharing Statement
Citations:
PubMed Identifier
23627666
Citation
Keating C, Dawood T, Barton DA, Lambert GW, Tilbrook AJ. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry. 2013 Apr 29;13:124. doi: 10.1186/1471-244X-13-124.
Results Reference
derived
Learn more about this trial
The Neurobiology of Depressive Illness
We'll reach out to this number within 24 hrs